Personalis (NASDAQ:PSNL) CFO Sells $1,117,541.04 in Stock

Personalis, Inc. (NASDAQ:PSNL) CFO Aaron Tachibana sold 103,668 shares of the business’s stock in a transaction that occurred on Tuesday, November 25th. The stock was sold at an average price of $10.78, for a total transaction of $1,117,541.04. Following the sale, the chief financial officer directly owned 164,458 shares of the company’s stock, valued at approximately $1,772,857.24. This trade represents a 38.66% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website.

Personalis Stock Performance

Shares of PSNL stock opened at $10.69 on Monday. The firm’s 50 day moving average price is $8.38 and its two-hundred day moving average price is $6.58. The stock has a market cap of $948.83 million, a PE ratio of -12.14 and a beta of 1.99. Personalis, Inc. has a 52-week low of $2.83 and a 52-week high of $11.40.

Personalis (NASDAQ:PSNL) last posted its quarterly earnings data on Tuesday, November 4th. The company reported ($0.24) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.28) by $0.04. Personalis had a negative return on equity of 38.25% and a negative net margin of 106.92%.The business had revenue of $14.50 million during the quarter, compared to the consensus estimate of $13.31 million. Personalis has set its FY 2025 guidance at EPS. Q4 2025 guidance at EPS. As a group, sell-side analysts predict that Personalis, Inc. will post -1.4 earnings per share for the current fiscal year.

Institutional Inflows and Outflows

Several institutional investors have recently modified their holdings of PSNL. Connor Clark & Lunn Investment Management Ltd. bought a new stake in shares of Personalis in the 2nd quarter valued at about $451,000. American Century Companies Inc. increased its position in Personalis by 33.9% during the first quarter. American Century Companies Inc. now owns 67,377 shares of the company’s stock worth $236,000 after buying an additional 17,056 shares during the last quarter. Trexquant Investment LP raised its stake in Personalis by 455.0% in the first quarter. Trexquant Investment LP now owns 122,959 shares of the company’s stock valued at $432,000 after buying an additional 100,804 shares during the period. Goldman Sachs Group Inc. lifted its position in shares of Personalis by 55.7% in the first quarter. Goldman Sachs Group Inc. now owns 284,426 shares of the company’s stock valued at $998,000 after buying an additional 101,706 shares during the last quarter. Finally, IQ EQ FUND MANAGEMENT IRELAND Ltd lifted its position in shares of Personalis by 67.0% in the second quarter. IQ EQ FUND MANAGEMENT IRELAND Ltd now owns 92,841 shares of the company’s stock valued at $609,000 after buying an additional 37,258 shares during the last quarter. 61.91% of the stock is currently owned by institutional investors and hedge funds.

Wall Street Analyst Weigh In

PSNL has been the topic of a number of recent research reports. HC Wainwright lifted their price objective on shares of Personalis from $8.50 to $10.00 and gave the company a “buy” rating in a report on Thursday, November 6th. BTIG Research lifted their price target on shares of Personalis from $11.00 to $12.00 and gave the company a “buy” rating in a research note on Tuesday, November 11th. Morgan Stanley boosted their price target on shares of Personalis from $5.00 to $9.00 and gave the stock an “equal weight” rating in a research report on Tuesday, November 11th. Needham & Company LLC raised their price objective on Personalis from $7.00 to $10.00 and gave the company a “buy” rating in a report on Wednesday, November 5th. Finally, Lake Street Capital reaffirmed a “buy” rating and issued a $11.00 target price on shares of Personalis in a research report on Wednesday, November 5th. Six analysts have rated the stock with a Buy rating, one has assigned a Hold rating and one has issued a Sell rating to the company’s stock. Based on data from MarketBeat, Personalis has an average rating of “Moderate Buy” and an average target price of $10.29.

About Personalis

Personalis, Inc develops and markets advanced cancer genomic tests and analytics primarily in the United States, Europe, and the Asia-Pacific. Its tests and analytics are used by pharmaceutical companies for translational research, biomarker discovery, and development of personalized cancer therapies, as well as advanced tests are used by physicians to detect cancer recurrence, monitor cancer evolution, and uncover insights for therapy selection.